Clinical Research Directory

Inclusion Criteria: * Aged 60 years or older at the time of informed consent. * Diagnosis of myelodysplastic syndromes (MDS) according to the World Health Organization (WHO) classification. * Intermediate-to-high-risk MDS, defined as at least one of the following: * International Prognostic Scoring System (IPSS) risk category of Intermediate-2 or High, with bone marrow blasts \<15%. * Revised International Prognostic Scoring System (IPSS-R) risk category of Intermediate, High, or Very High, with bone marrow blasts \<15%. * Intermediate-1 risk MDS with grade 1 to 3 anemia and not suitable for hypomethylating agent therapy. * Evidence of persistent cytopenia affecting one or more hematopoietic lineages for at least 4 months, unless MDS-associated cytogenetic abnormalities or increased blasts are present. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Adequate organ function as assessed by laboratory tests within 7 days before enrollment, including liver, renal, and cardiac function, in the opinion of the investigator. * Ability to understand and willingness to sign a written informed consent form. Exclusion Criteria: * Bone marrow blasts \>=15% at screening. * Prior treatment with chidamide. * Concurrent diagnosis of acute myeloid leukemia (AML) or other active hematologic malignancy. * Receipt of intensive chemotherapy, hypomethylating agents, or other investigational agents within 4 weeks before enrollment. * Uncontrolled active infection or severe concurrent medical condition that, in the investigator's judgment, would interfere with study participation. * Clinically significant cardiac disease, including uncontrolled arrhythmia or clinically relevant QT interval prolongation. * Known hypersensitivity to chidamide or any of its excipients. * Participation in another interventional clinical trial at the time of enrollment. * Any condition that, in the investigator's judgment, would make the participant unsuitable for participation in this study.